Bile Duct Cancer Market

Bile duct cancer Overview

Cholangiocarcinoma or Bile Duct Cancers arise from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Cholangiocarcinomas are the most common biliary tract malignancy and based on its location, classified as intrahepatic, perihilar and extrahepatic– the latter two were previously grouped as extrahepatic cholangiocarcinoma. Most occur without a clear cause, although certain factors can increase the risk of getting it. Cholangiocarcinoma symptoms include yellowing of the skin and whites of the eyes (jaundice), itchy skin, pale stools and dark urine, loss of appetite and weight loss, persistent tiredness, abdominal pain and swelling, high fever, chills and shivering and many others. Bile Duct Cancers are more common in males than females and usually affects patients who are between 50-70 years of age.

Bile duct cancer Epidemiology

Primary biliary tract malignancies affect one in every 100,000 people per year in the United States, and it has been found that more than 95% of these malignancies are Bile duct cancer (epithelial adenocarcinomas) frequently found in the extrahepatic biliary tree. In the United States, there are approximately 5,000 new cases. Bile duct cancer diagnosed each year. The age-adjusted rates for cholangiocarcinoma in the US are highest among Hispanics and Asians (2.8–3.3/100,000) and lowest among non-Hispanic whites and blacks (2.1/100,000). Extrahepatic and perihilar CCA are the most common types with 6–8% of CCAs being intrahepatic, 50–67% perihilar and 27–42% distal extrahepatic.

Bile duct cancer is slightly more prevalent in males than females (1.3:1.0) and usually affects the patient in the fifth to the seventh decade of life. Furthermore, among the types, it has been observed that the incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40 years (1973-2012). In the United States, incidence rates of intrahepatic cholangiocarcinoma have increased by 165% between the late 1970s and the late 1990s from 0.32/100,000 to 0.85/100,000.

Bile duct cancer Treatment

Bile duct cancer treatment depends on the size and location of the tumour. The current standard cholangiocarcinoma treatment includes Surgery, Photodynamic therapies, Targeted therapies, Radio sensitizers and Chemotherapies. The primary bile duct cancer treatment is surgery, however radiation therapy (external beam radiation therapy and Brachytherapy) and chemotherapy are used if surgery is not active like incase of both stage III and stage IV cancers which cannot be completely removed surgically.

The use of locoregional therapies in patients with intrahepatic cholangiocarcinoma is also being established. Different methods of intra-arterial therapy include bland embolization, trans-arterial chemoembolization (TACE), the use of drug-eluting beads and radioembolisation. Better ways to use laparoscopic surgery are also being tested and compared to open surgery. Adjuvant and neoadjuvant treatments are also active areas of research interest as well.

Lately, there has been a rise in bile duct cancer awareness among physicians, improvement in imaging techniques and new pathology tests, which together contribute to an increase in several diagnoses, particularly of intrahepatic cholangiocarcinoma. This increase in diagnosis, rising incidence and awareness, rich emerging pipeline, a better understanding of the genetic mutations, along with the testing of targeted drugs and immunotherapies in people with this disease are laying the groundwork for long-awaited advances in the treatment therapies. These factors have led to impact the treatment of Bile Duct Cancer market size in the upcoming years.

Bile duct cancer market

Many key players such as Agios Pharmaceuticals, Incyte Corporation, Sirtex Medical, Delcath Systems, Immunitor LLC, Jiangsu HengRui Medicine, and many others are developing therapies for Bile Duct Cancer treatment. Therapies for Bile Duct Cancer market treatment are AG-120 (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Melphalan / HDS (Delcath Systems), Cisplatin-gemcitabine (Sirtex Medical), Apatinib (Jiangsu HengRui Medicine), and others along with other compelling treatment options in the clinical trials is expected to increase the overall Bile Duct Cancer market size in the upcoming years.